RGC
Income statement / Annual
Last year (2024), Regencell Bioscience Holdings Limited's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Regencell Bioscience Holdings Limited's net income was -$4.30 M.
See Regencell Bioscience Holdings Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
01/01/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$3.16 B |
$3.20 B |
$3.13 B |
$2.99 B |
| Cost of Revenue |
$745,588.00
|
$769,687.00
|
$604,397.00
|
$26,456.00
|
$9,516.00
|
$0.00
|
$123.00 M
|
$1.23 B
|
$1.21 B
|
$111.00 M
|
| Gross Profit |
-$745,588.00
|
-$769,687.00
|
-$604,397.00
|
-$26,456.00
|
-$9,516.00
|
$0.00
|
$3.04 B
|
$1.97 B
|
$1.92 B
|
$2.88 B
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0.96
|
0.62
|
0.61
|
0.96
|
| Research and Development Expenses |
$1.07 M
|
$1.58 M
|
$2.51 M
|
$438,323.00
|
$386,230.00
|
$228,223.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$3.22 M
|
$4.43 M
|
$5.08 M
|
$941,463.00
|
$311,934.00
|
$159,129.00
|
$86.60 M
|
$512.20 M
|
$500.30 M
|
$74.40 M
|
| Selling & Marketing Expenses |
$125,427.00
|
$262,664.00
|
$25,275.00
|
$1,576.00
|
$114,207.00
|
$3,638.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$2.92 M
|
$4.69 M
|
$5.11 M
|
$943,039.00
|
$426,141.00
|
$162,767.00
|
$86.60 M
|
$512.20 M
|
$500.30 M
|
$74.40 M
|
| Other Expenses |
$0.00
|
$211,342.00
|
$23,215.00
|
$34,617.00
|
$0.00
|
$0.00
|
$1.22 B
|
$1.11 B
|
$1.08 B
|
$1.12 B
|
| Operating Expenses |
$3.99 M
|
$6.27 M
|
$7.62 M
|
$1.38 M
|
$812,371.00
|
$390,990.00
|
$1.31 B
|
$1.63 B
|
$1.58 B
|
$1.19 B
|
| Cost And Expenses |
$4.74 M
|
$6.27 M
|
$7.62 M
|
$1.38 M
|
$812,371.00
|
$390,990.00
|
$2.89 B
|
$2.85 B
|
$2.79 B
|
$2.68 B
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$745,588.00
|
$769,687.00
|
$604,397.00
|
$26,456.00
|
$9,516.00
|
$390,990.00
|
$254.80 M
|
$230.70 M
|
$216.80 M
|
$212.00 M
|
| EBITDA |
-$3.62 M |
-$5.29 M |
-$6.99 M |
-$1.35 M |
-$802,855.00 |
-$390,990.00 |
$468.70 M |
$512.30 M |
$470.30 M |
$391.00 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0.15
|
0.16
|
0.15
|
0.13
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0.09
|
0.11
|
0.11
|
0.1
|
| Total Other Income/Expenses Net |
$373,505.00
|
$211,342.00
|
$23,215.00
|
$34,617.00
|
$0.00
|
$0.00
|
-$57.80 M
|
-$62.50 M
|
-$85.70 M
|
-$127.80 M
|
| Income Before Tax |
-$4.36 M
|
-$6.06 M
|
-$7.59 M
|
-$1.35 M
|
-$812,371.00
|
-$390,990.00
|
$213.90 M
|
$281.70 M
|
$253.30 M
|
$178.60 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0.07
|
0.09
|
0.08
|
0.06
|
| Income Tax Expense |
$0.00
|
-$191,199.00
|
-$171,827.00
|
-$210,102.00
|
-$1.00
|
-$390.99
|
$101.60 M
|
$111.20 M
|
$100.10 M
|
$73.40 M
|
| Net Income |
-$4.30 M
|
-$5.87 M
|
-$7.42 M
|
-$1.35 M
|
-$812,371.00
|
-$390,990.00
|
$112.30 M
|
$170.40 M
|
$153.40 M
|
$105.60 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0.04
|
0.05
|
0.05
|
0.04
|
| EPS |
-0.33 |
-0.45 |
-0.57 |
-0.11 |
-0.0643 |
-0.0309 |
0.72 |
1.09 |
0.98 |
0.68 |
| EPS Diluted |
-0.33 |
-0.45 |
-0.57 |
-0.11 |
-0.0643 |
-0.0309 |
0.72 |
1.09 |
0.98 |
0.68 |
| Weighted Average Shares Out |
$13.01 M
|
$13.01 M
|
$13.01 M
|
$12.64 M
|
$12.64 M
|
$12.64 M
|
$156.34 M
|
$156.79 M
|
$156.45 M
|
$155.29 M
|
| Weighted Average Shares Out Diluted |
$13.01 M
|
$13.01 M
|
$13.01 M
|
$12.64 M
|
$12.64 M
|
$12.64 M
|
$156.99 M
|
$156.80 M
|
$156.50 M
|
$156.31 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
